The goal of this study is to Multikine as first-line standard of care therapy in treating newly diagnosed, the first study not treated head and neck cancer patients kidney and bladder infection . Believed to be believed to be the largest head and neck cancer trial ever conducted and is called ‘IT issues ‘, an acronym for: Immunotherapy Multikine anticancer treatments. – ‘We are very excited to begin this pivotal trial in the first center outside the U.S.,’said Geert Kersten, Chief Executive Officer of CEL-SCI. ‘We expect foreign centers, a significant number of patients, the compression of time necessary study will study will attract. ‘.
Phase II clinical trials Multikine showed the product to be safe and well tolerated and eliminated tumors in 12 percent of subjects, the patient population for the for the phase III trial. After 3 weeks after 3 weeks of treatment, the same treatment regimen in phase in the phase III clinical trial. The Multikine treatment regimen was also shown to kill, on average, about half of the cancer cells in the subjects showed ‘ tumors before the start of standard therapy. Follow-up studies of patients in the ‘proof of concept ‘enrolled Phase II study a 33 percent improvement in the survival rate of patients with Multikine at a median of three treated and six months after the operation. U.S. Food and Drug Administration granted orphan drug status in the neoadjuvant therapy of patients with squamous cell carcinoma of the head and neck Multikine.
Sound Medical Solutions Group ExAblate and ExAblate 2000 are trademarks of InSightec is.